Sjogren Syndrome Market
Global Sjogren Syndrome Market Size, Share & Trends Analysis Report by Type (Primary Sjögren’s Syndrome and Secondary Sjögren’s Syndrome), by Drug Type (Pilocarpine, Cyclosporine, Hydroxychloroquine, and Immunosuppressive Agents), and by Test (Blood Test, Eye Test, Imaging Test, and Biopsy) Forecast Period (2022-2028)
The global Sjogren's syndrome market is anticipated to grow at a significant CAGR of 4.6% during the forecast period. Sjogren’s syndrome is a disorder of the human immune system whereby it affects the parts of the body that produces fluids such as saliva, and tears. It's a long-term condition that affects one's daily life and is more common in women than men which usually starts at age 40 to 60. Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, and blood vessels. The treatment focuses on relieving the symptoms such as fiving artificial tears for dry eyes, sucking sugar-free candies, and drinking gallons of water for dry mouth along with taking some medicines. The factors contributing to the market growth include a growing population with several diseases that can cause Sjogren’s syndrome and increasing demand for advanced treatment for Sjogren’s syndrome.
However, a lack of awareness among the population about Sjogren’s syndrome restrains the growth of the market. Further lack of proper cure treatments is also projected to hamper the growth of the market. Currently, available treatment options are either ineffective in patients with the following syndrome or only relieve the symptoms. Increasing lab automation rates and technological advances will bring opportunities for the growth of the market.
Impact of COVID-19 Pandemic on Global Sjogren’s Syndrome Market
Due to COVID-19, this Sjogren's syndrome market witnessed high growth during the period owing to increasing awareness about healthy lifestyle and mainly due to COVID-19 directly attacking the people with low immune systems and it was a great opportunity for the market to grow. This market has upsurge growth during it also due to hydroxychloroquine drugs was in demand to manage COVID-19, attributed to its high demand the market has accounted high growth. Moreover, pharmaceutical and biotechnology industry companies have witnessed high growth owing to an increase in demand for high immune-boosting medicines and products and also demand for vaccine and treatment drugs for COVID-19.
Segmental Outlook
The Sjogren's syndromes are segmented based on type, drug type, and test. Based on type, the market is subdivided into primary sjögren’s syndrome and secondary sjögren’s syndrome. Based on a drug type, the market is sub-classified into pilocarpine, cyclosporine, hydroxychloroquine, and immunosuppressive agents. On this basis, the test market is sub-segmented into blood tests, Eye tests, imaging tests, and biopsy. Among the drug tye segment, the Hydroxychloroquine drug type is dominating owing to it suppressing the immune system methotrexate (Trexall) and also it is the safest drug to treat the disease and major drugs are FDA approved.
Global Sjogren’s Syndrome Market Share by, 2021 (%)
The Secondary Sjögren’s Segment is Dominating the Global Sjogren’s Syndrome Market
Secondary Sjögren’s syndrome is projected to hold a significant share in the global sjögren’s syndrome market. The factors contributing to the market growth include the growing prevalence of autoimmune diseases such as rheumatoid arthritis. One of the most common causes of secondary Sjogren syndrome includes rheumatoid arthritis. This kind of diagnosis has the following conditions primary biliary cholangitis, lupus, scleroderma, and others. In secondary Sjogren's syndrome, the doctor will be going through complete medical history and conducting a physical exam. The diagnosis will be including blood work that usually looks for proteins and markers specific to Sjogren’s. It also includes a lower lip biopsy to look for clusters of inflammatory cells.
Regional Outlooks
The global Sjogren's syndrome market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America. North America is dominating owing to the increased prevalence of Sjogren's syndrome diseases across the region that is followed by Europe.
Global Sjogren’s Syndrome Market Growth, by Region 2022-2028
The Asia Pacific Region is Fastest Growing in the Global Sjogren’s Syndrome market
Asia Pacific region is forecasted to exhibit rapid growth in Sjogren’s syndrome market due to rising healthcare infrastructure in the region, the rise of diagnosis of Sjogren’s disease, and increasing government expenditure in the healthcare sector are driving the growth of the Sjogren market in the region. According to Sage publications 2019, almost 68.59% of Chinese patients had dry eye prevalence, and 86.5% had dry mouth prevalence in Chinese patients additionally 6.9% of Chinese patients had arthritis. Further, the increasing prevalence of Sjogren’s syndrome and the rise of such diagnoses also drive the growth of the market. However, lack of proper treatment options, lack of awareness, and affordability are the factors restraining the growth of the market in underdeveloped countries such as the Middle East and Africa.
Market Players Outlook
The major players that contribute to the growth of the global Sjogrens syndrome market include AbbVie Inc., Argentis Pharmaceuticals, LLC, AstraZeneca PLC, Bristol-Myers Squibb Co., Novartis International AG, Pfizer Inc., Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new Deployment launches, to stay competitive in the market. For instance, in July 2020, UniQuest and CSL Ltd partnered, to develop and commercialize antigen immune tolerance induction technology which is used in treating Sjogren’s syndrome. This collaboration was mainly focused to identify liposome-encapsulated antigen candidates for Sjogren's syndrome and then separating the lead candidate for its clinical trials. This technology is used to treat patients suffering from autoimmune diseases.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Sjogren's syndrome market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1.Report Summary
?Current Product Analysis and Growth Potential Outlook
?Impact of COVID-19 on the Global Sjogren’s Syndrome Market
?Recovery Scenario of Global Sjogren’s Syndrome Market
1.1.Research Methods and Tools
1.2.Market Breakdown
1.2.1.By Segments
1.2.2.By Region
2.Market Overview and Insights
2.1.Scope of the Report
2.2.Analyst Insight & Current Market Trends
2.2.1.Key Findings
2.2.2.Recommendations
2.2.3.Conclusion
3.Competitive Landscape
3.1.Key Company Analysis
3.1.1.Overview
3.1.2.Financial Analysis
3.1.3.SWOT Analysis
3.1.4.Recent Developments
3.2.Key Strategy Analysis
3.3.Impact of COVID-19 on Key Players
4.Market Segmentation
4.1.Global Sjogren’s Syndrome Market by Type
4.1.1.Primary Sjögren’s Syndrome
4.1.2.Secondary Sjögren’s Syndrome
4.2.Global Sjogren’s Syndrome Market by Drug Type
4.2.1.Pilocarpine
4.2.2.Cyclosporine
4.2.3.Hydroxychloroquine
4.2.4.Immunosuppressive Agents
4.3.Global Sjogren’s Syndrome Market by Test
4.3.1.Blood Test
4.3.2.Eye Test
4.3.3.Imaging Test
Biopsy
5.Regional Analysis
5.1.North America
5.1.1.US
5.1.2.Canada
5.2.Europe
5.2.1.UK
5.2.2.Germany
5.2.3.Italy
5.2.4.Spain
5.2.5.France
5.2.6.Rest of Europe
5.3.Asia-Pacific
5.3.1.China
5.3.2.India
5.3.3.Japan
5.3.4.South Korea
5.3.5.Rest of Asia-Pacific
Rest of the World
6.Company Profiles
6.1.AbbVie Inc.
6.2.Amgen Inc.
6.3.Argentis Pharmaceuticals, LLC
6.4.AstraZeneca
6.5.Aldeyra Therapeutics, Inc.
6.6.Bristol-Myers Squibb Co.
6.7.Biogen Inc.
6.8.Demcon Hemics BV.
6.9.Daiichi Sankyo Co., Ltd.
6.10.Eisai Co., Ltd.
6.11.F. Hoffmann-La Roche Ltd.
6.12.Gilead Sciences, Inc.
6.13.Horizon Therapeutics
6.14.Johnson and Johnson Service Inc.
6.15.Novartis International AG
6.16.Otsuka Pharmaceutical Co., Ltd.
6.17.ONO PHARMACEUTICAL CO., LTD
6.18.Pfizer Inc.
6.19.RemeGen, Ltd.
6.20.Sanofi S.A
6.21.Sun Pharmaceutical Industries Ltd.
6.22.TearSolutions
1.GLOBAL SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2.GLOBAL PRIMARY SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3.GLOBAL SECONDARY SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4.GLOBAL SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
5.GLOBAL PILOCARPINE FOR SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6.GLOBAL CYCLOSPORINE FOR SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7.GLOBAL HYDROXYCHLOROQUINE FOR SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8.GLOBAL IMMUNOSUPPRESSIVE AGENTS FOR SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9.GLOBAL SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
10.GLOBAL SJOGREN’S SYNDROME IN BLOOD TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11.GLOBAL SJOGREN’S SYNDROME IN EYE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12.GLOBAL SJOGREN’S SYNDROME IN IMAGING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13.GLOBAL SJOGREN’S SYNDROME IN BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14.GLOBAL SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
NORTH AMERICAN SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16.NORTH AMERICAN SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17.NORTH AMERICAN SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
18.NORTH AMERICAN SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
19.EUROPEAN SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20.EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21.EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
22.EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY DRUG TEST, 2021-2028 ($ MILLION)
23.ASIA-PACIFIC SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24.ASIA-PACIFIC SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
25.ASIA-PACIFIC SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
26.ASIA-PACIFIC SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
27.REST OF THE WORLD SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
28.REST OF THE WORLD SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
29.REST OF THE WORLD SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
30.REST OF THE WORLD SJOGREN’S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
1.IMPACT OF COVID-19 ON GLOBAL SJOGREN’S SYNDROME MARKET, 2021-2028 ($ MILLION)
2.IMPACT OF COVID-19 ON GLOBAL SJOGREN’S SYNDROME MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3.RECOVERY OF GLOBAL SJOGREN’S SYNDROME MARKET, 2022-2028 (%)
4.GLOBAL SJOGREN’S SYNDROME MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5.GLOBAL PRIMARY SJOGREN’S SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6.GLOBAL SECONDARY SJOGREN’S SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7.GLOBAL SJOGREN’S SYNDROME MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
8.GLOBAL PILOCARPINE FOR SJOGREN’S SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9.GLOBAL CYCLOSPORINE FOR SJOGREN’S SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10.GLOBAL HYDROXYCHLOROQUINE FOR SJOGREN’S SYNDROME MARKET SHARE BY TREATMENTS, 2021 VS 2028 (%)
11.GLOBAL SJOGREN’S SYNDROME MARKET SHARE BY TEST, 2021 VS 2028 (%)
12.GLOBAL SJOGREN’S SYNDROME IN BLOOD TEST MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13.GLOBAL SJOGREN’S SYNDROME IN EYE TEST MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14.GLOBAL SJOGREN’S SYNDROME IN IMAGING TEST MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15.GLOBAL SJOGREN’S SYNDROME IN BIOPSY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16.GLOBAL SJOGREN’S SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17.US SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
18.CANADA SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
19.UK SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
20.FRANCE SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
21.GERMANY SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
22.ITALY SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
23.SPAIN SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
24.REST OF EUROPE SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
25.INDIA SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
26.CHINA SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
27.JAPAN SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
28.SOUTH KOREA SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
29.REST OF ASIA-PACIFIC SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
30.REST OF THE WORLD SJOGREN’S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
